Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01181531
Other study ID # 20090686
Secondary ID PARADIGM
Status Completed
Phase Phase 4
First received
Last updated
Start date October 1, 2010
Est. completion date August 14, 2012

Study information

Verified date September 2018
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of treatment with cinacalcet to manage plasma parathyroid levels as to compared traditional vitamin D therapy, whether given orally or intravenously, among hemodialysis subjects with secondary hyperparathyroidism when the doses are adjusted appropriately to maintain serum calcium and phosphorous levels with currently recommended ranges.


Recruitment information / eligibility

Status Completed
Enrollment 312
Est. completion date August 14, 2012
Est. primary completion date July 17, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years at screening

- Treated with maintenance hemodialysis 3 times a week for = 3 months prior to screening

- Informed consent provided by the study candidate

- For subjects NOT receiving cinacalcet and/or vitamin D therapy for SHPT within 60 days prior to enrollment: Plasma PTH levels = 450 pg/mL (50 pmol/L) during screening, as obtained from the central laboratory and, Serum corrected total calcium = 8.4 mg/dL (2.1 mmol/L) and < 10.2 mg/dL (2.55 mmol/L) during screening, as obtained from the central laboratory

Exclusion Criteria:

- Parathyroidectomy in the 12 weeks before the date of informed consent

- History of seizure within 12 weeks prior to randomization

- Scheduled for kidney transplant

- Parathyroidectomy anticipated within the next 6 months

- Liver function tests > than 2 x the Upper Limit of Normal

- Prior use of bisphosphonates, or expected to receive bisphosphonates during the trial

- Subject has previously enrolled in this study

- General

- Other investigational procedures are excluded

- Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)

- Subject (male or female) is not willing to use highly effective contraception during treatment and for at least one month (women) and 3 months (men) after the end of treatment

- Subject is pregnant or breast feeding, or planning to become pregnant during study or within 1 month after the end of treatment Male subject with a pregnant partner who is not willing to use a condom during treatment and for at least 1 month after the end of treatment

- Subject has known sensitivity or intolerance to any of the protocol required therapies

- Subject will not be available for protocol-required study visits, to the best of the subject and investigator's knowledge

- Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures

Study Design


Intervention

Drug:
Traditional Vitamin D Therapy
Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
Cinacalcet
Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

References & Publications (1)

Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1031-40. doi: 10.2215/CJN.07050714. Epub 2015 Apr 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline in Mean PTH During Efficacy Assessment Phase (EAP) Mean PTH during EAP is defined as the mean of values at study weeks 40, 44, 48 and 52 Baseline to week 40-52
Secondary Treatment Comparison of >=30% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase (EAP) Number of participants achieving a >=30% Reduction From Baseline in Mean PTH During Efficacy Assessment Phase (EAP) Baseline to week 40-52
Secondary Treatment Comparison of Plasma PTH < 300 pg/mL During Efficacy Assessment Phase (EAP) Number of participants achieving Plasma PTH < 300 pg/mL During Efficacy Assessment Phase (EAP) week 40-52
See also
  Status Clinical Trial Phase
Completed NCT01134562 - Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Phase 1
Completed NCT02523209 - Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation N/A
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT05382988 - Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Phase 3
Completed NCT02056730 - The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Phase 4
Completed NCT01704079 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3
Completed NCT00397475 - Evaluation of Colecalciferol Substitution in Dialysis Patients N/A
Withdrawn NCT03063190 - Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Phase 4
Completed NCT02102204 - Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Recruiting NCT02273570 - Optimal Anemia Treatment in End Stage Renal Disease (ERSD) N/A
Completed NCT01788046 - Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Phase 3
Completed NCT01785849 - Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Terminated NCT01277510 - Pediatric Chronic Kidney Disease Safety and Efficacy Phase 3
Terminated NCT01439867 - Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Phase 2
Completed NCT01134549 - Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers Phase 1
Completed NCT01785875 - Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Phase 3
Active, not recruiting NCT02464072 - Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis N/A
Completed NCT01290029 - Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease Phase 1